Ikena Oncology Stock Analysis

IKNA Stock  USD 1.37  0.06  4.58%   
Ikena Oncology is overvalued with Real Value of 1.16 and Hype Value of 1.37. The main objective of Ikena Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Ikena Oncology is worth, separate from its market price. There are two main types of Ikena Oncology's stock analysis: fundamental analysis and technical analysis.
The Ikena Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ikena Oncology's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

Ikena Stock Analysis Notes

About 88.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ikena Oncology recorded a loss per share of 1.02. The entity had not issued any dividends in recent years. Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To learn more about Ikena Oncology call Mark Manfredi at 857 273 8343 or check out https://ikenaoncology.com.

Ikena Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ikena Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ikena Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ikena Oncology generated a negative expected return over the last 90 days
Ikena Oncology may become a speculative penny stock
Ikena Oncology has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (49.23 M) with loss before overhead, payroll, taxes, and interest of (30.88 M).
Ikena Oncology currently holds about 192.81 M in cash with (46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 88.0% of the company shares are owned by institutional investors

Ikena Oncology Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ikena Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Ikena Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.22 M.

Technical Drivers

As of the 22nd of March, Ikena Oncology retains the Standard Deviation of 2.5, risk adjusted performance of (0.1), and Market Risk Adjusted Performance of (3.16). Ikena Oncology technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Ikena Oncology Price Movement Analysis

The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ikena Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ikena Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Ikena Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ikena Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ikena Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ikena Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Zhang Xiaoyan Michelle over a week ago
Disposition of 964 shares by Zhang Xiaoyan Michelle of Ikena Oncology at 12.0 subject to Rule 16b-3
 
Orbimed Advisors Llc over two weeks ago
Acquisition by Orbimed Advisors Llc of 353192 shares of Ikena Oncology subject to Rule 16b-3
 
Zhang Xiaoyan Michelle over a month ago
Acquisition by Zhang Xiaoyan Michelle of 964 shares of Ikena Oncology at 2.1462 subject to Rule 16b-3
 
Orbimed Advisors Llc over two months ago
Acquisition by Orbimed Advisors Llc of 353192 shares of Ikena Oncology subject to Rule 16b-3
 
Atlas Venture Fund Xi, L.p. over three months ago
Disposition of 11989 shares by Atlas Venture Fund Xi, L.p. of Ikena Oncology at 15.03 subject to Rule 16b-3
 
Dukes Iain D. over three months ago
Acquisition by Dukes Iain D. of 23419 shares of Ikena Oncology at 14.92 subject to Rule 16b-3
 
Santillana Sergio L. over three months ago
Acquisition by Santillana Sergio L. of 70400 shares of Ikena Oncology at 11.45 subject to Rule 16b-3
 
Dukes Iain D. over three months ago
Acquisition by Dukes Iain D. of 23419 shares of Ikena Oncology at 14.92 subject to Rule 16b-3
 
Mark Manfredi over three months ago
Acquisition by Mark Manfredi of 238900 shares of Ikena Oncology at 9.76 subject to Rule 16b-3
 
Hughes Owen over six months ago
Acquisition by Hughes Owen of 17520 shares of Ikena Oncology at 1.75 subject to Rule 16b-3
 
Stampacchia Otello over six months ago
Acquisition by Stampacchia Otello of 17520 shares of Ikena Oncology at 1.75 subject to Rule 16b-3
 
Germa Caroline over a year ago
Acquisition by Germa Caroline of 579100 shares of Ikena Oncology at 1.47 subject to Rule 16b-3

Ikena Oncology Outstanding Bonds

Ikena Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ikena Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ikena bonds can be classified according to their maturity, which is the date when Ikena Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Ikena Oncology Predictive Daily Indicators

Ikena Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ikena Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ikena Oncology Forecast Models

Ikena Oncology's time-series forecasting models are one of many Ikena Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ikena Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ikena Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ikena Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ikena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ikena Oncology. By using and applying Ikena Stock analysis, traders can create a robust methodology for identifying Ikena entry and exit points for their positions.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Ikena Oncology to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Complementary Tools for Ikena Stock analysis

When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
CEOs Directory
Screen CEOs from public companies around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume